INTRASENSE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.316 EUR | -3.66% |
|
-2.77% | -12.22% |
| Apr. 17 | Intrasense: an innovative solution for cancer monitoring | CF |
| Apr. 09 | Guerbet: CE certificate for a platform | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1,200 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system.
Calendar
2024-07-10
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.22% | 17.61M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- ALINS Stock
- News Intrasense
- Intrasense Partners with Software Company EDL for Myrian Distribution
